Expert Interview
A Second Look: Discussing the recent approval of Zynyz (Retifanlimab) from Incyte in merkel cell carcinoma (MCC).
Ticker(s): INCYInstitution: Moffitt
- Senior member, chief academic officer, director of regional therapies, cutaneous oncology department at Moffitt's cancer center
- Professor of Surgery at the University of South Florida, Morsani School of Medicine.
- Research and clinical interests include the regional therapy treatment of cutaneous melanoma and non-melanoma skin cancers, soft tissue sarcomas.
How many MCC patients do you treat annually?
Added By: wilson_adminCan you describe SoC for MCC?
Added By: wilson_adminHow do you think you would use Zynyz in this indication?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
